Metabolic benefits associated with sibutramine therapy

Sibutramine-induced weight loss and weight maintenance lead to clinically relevant reductions in risk factors associated with the metabolic syndrome. Treatment with the drug decreases visceral fat, improves lipid levels, decreases glycosylated haemoglobin and decreases uric acid concentrations. Sibu...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Obesity 2002-12, Vol.26 (4), p.S34-S37
Main Author: Krejs, G.J
Format: Article
Language:English
Subjects:
Diabetes
Drug dosages
drug therapy
glycosylation
hemoglobin
Laboratories
Lifestyles
Lipids
Metabolic disorders
Metabolic syndrome
noninsulin-dependent diabetes mellitus
Obesity
Overweight
patients
prediction
risk
Risk factors
uric acid
visceral fat
Weight control
weight loss
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sibutramine-induced weight loss and weight maintenance lead to clinically relevant reductions in risk factors associated with the metabolic syndrome. Treatment with the drug decreases visceral fat, improves lipid levels, decreases glycosylated haemoglobin and decreases uric acid concentrations. Sibutramine is effective in achieving weight loss in patients with type 2 diabetes but weight loss occurs more slowly than in non-diabetic patients. The criteria for predicting response to treatment in uncomplicated patients may not be appropriate to those with type 2 diabetes. Furthermore, it is important to set realistic goals for weight loss in type 2 diabetes to avoid the risk of denying effective treatment to patients.
ISSN:0307-0565
1476-5497
DOI:10.1038/sj.ijo.0802217